| DB ID | MyCo_2313 |
| Title | Diagnostic value of serum human Galactomannan aspergillus antigen and 1,3-beta-D-glucan in immunocompromised patient suspected fungal infection |
| Year | 2021 |
| PMID | 33945177 |
| Fungal Diseases involved | Fungal infection |
| Associated Medical Condition | None |
| Genus | None |
| Species | None |
| Organism | None |
| Ethical Statement | This study was approved by the ethical committee of Dr. Saiful Anwar General Hospital, Malang, Indonesia (ethical number 400/109/K.3/302/2018). All patients included in this study were asked to sign a consent form (Informed Consent). |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Indonesia |
| Cohort | This study was conducted for six months, from July to December 2018. The inclusion criteria were patients 18–70 years old, with the risk of fungal infection (immunocompromised patients). The immunocompromised patients' criteria were HIV or AIDS infection, cancer, solid organ transplantation, sickle cell disease or chronic inflammatory conditions. Laboratory tests criteria of immunocompromised patients were CD4T cells <500 or absolute lymphocytes <1000 cells/μl for adults.14 The exclusion criteria were patient who previously received antifungal therapy. A total of 86 subjects consisting of 44 fungal infections and 42 no fungal infections. Subjects aged 18–70 years old with a mean aged of 51 years for fungal infection patients and 54 years old for subjects with no fungal infection. Most of the sex is male. Of the 44 subjects with a fungal infection, 26 (59.0%) subjects had positive culture results. Of the 86 subjects who were immunocompromised patients, 20 (23.2%) got HIV, 33 (38.3%) subjects with cancer, and the remaining subjects had the other immunocompromised condition. |
| Cohort No. | 86 patients |
| Age Group | 32-87 |
| P Value | p< 0.05 |
| Sensitivity | 0.712 |
| Specificity | 0.524 |
| Positive Predictive Value | 0.6154 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | Human Aspergillus Galactomannan (GAL) Antigen ELISA Kit (Sincere Biotech), human 1,3-beta- D- glucan (BAL) (Sincere Biotech). |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
